Scott A. Summers
YOU?
Author Swipe
View article: The Role of Sphingolipids in Myocardial Recovery Mediated by Mechanical Unloading and Circulatory Support
The Role of Sphingolipids in Myocardial Recovery Mediated by Mechanical Unloading and Circulatory Support Open
Myocardial recovery after left ventricular assist device (LVAD) support is a critical phenomenon that allows advanced heart failure patients to retain their native heart. We quantified targeted sphingolipids in serum and cardiac tissue of …
View article: JMJD8 facilitates hepatic lipid deposition and metabolic dysfunction
JMJD8 facilitates hepatic lipid deposition and metabolic dysfunction Open
This study identifies Jumonji domain-containing 8 (JMJD8) as a previously unrecognized driver of hepatic steatosis and metabolic dysfunction in diet-induced fatty liver disease. Liver-specific deletion of Jmjd8 protects against triglycerid…
View article: Cardiolipin deficiency disrupts electron transport chain to drive steatohepatitis
Cardiolipin deficiency disrupts electron transport chain to drive steatohepatitis Open
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive disorder marked by lipid accumulation, leading to metabolic dysfunction-associated steatohepatitis (MASH). A key feature of the transition to MASH involves o…
View article: Cardiolipin deficiency disrupts electron transport chain to drive steatohepatitis
Cardiolipin deficiency disrupts electron transport chain to drive steatohepatitis Open
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive disorder marked by lipid accumulation, leading to metabolic dysfunction-associated steatohepatitis (MASH). A key feature of the transition to MASH involves o…
View article: Murine Models of Obesity-Related Cancer Risk
Murine Models of Obesity-Related Cancer Risk Open
Obesity is a global menace that has impacted more than 14% of adults worldwide and more than a third of Americans. Importantly, obesity is associated with an increased risk of more than 13 types of cancer and worse outcomes, including incr…
View article: Metabolite perturbations in type 1 diabetes associated with metabolic dysfunction-associated steatotic liver disease
Metabolite perturbations in type 1 diabetes associated with metabolic dysfunction-associated steatotic liver disease Open
Background Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Although MASLD has been widely studied in person…
View article: The role of sphingolipids in heart failure
The role of sphingolipids in heart failure Open
Advanced heart failure (HF) is characterized by changes in the structure, function, and metabolism of cardiac muscle. As the disease progresses, cardiomyocytes shift their ATP production from fatty acid oxidation to glycolysis. This shift …
View article: Data from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Data from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Body mass index (BMI) may misclassify obesity-related cancer (ORC) risk, as metabolic dysfunction can occur across BMI levels. We hypothesized that metabolic dysfunction at any BMI increases ORC risk compared with normal BMI without metabo…
View article: Supplemental Table 3 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 3 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 3. Association between metabolic phenotypes defined by ATP III criteria with obesity-related cancer risk in the Women’s Health Initiative cohort (N= 23,915).
View article: Supplemental Table 6 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 6 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 6. Association between metabolic phenotypes defined by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) with obesity-related cancer risk in the Women’s Health Initiative cohort (N= 23,232).
View article: Supplemental Table 2 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 2 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 2. Association between metabolic phenotypes defined by Wildman criteria with obesity-related cancer risk in the Women’s Health Initiative cohort (N= 20,593).
View article: Supplemental Figure 3 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Figure 3 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Figure 3. Kaplan–Meier cumulative incidence curves for obesity-related cancer risk among Women’s Health Initiative (WHI) participants according to metabolic phenotype defined by (A) Wildman criteria, (B) ATP III criteria, (C) …
View article: Supplemental Figure 2 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Figure 2 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Figure 2. Directed Acyclic Graph (DAG). Directed Acyclic Graph (DAG) illustrating potential causal relationships among covariates, exposure, and outcome measures in this study.
View article: Supplemental Table 8 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 8 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 8. Association between individual metabolic dysfunction components with obesity-related cancer risk in the Women’s Health Initiative cohort (N= 20,593).
View article: Supplemental Table 4 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 4 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 4. Association between metabolic phenotypes defined by high sensitivity C-Reactive Protein (hs-CRP) ≥ 3 mg/L with obesity-related cancer risk in the Women’s Health Initiative cohort (N= 21,245).
View article: Supplemental Table 1 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 1 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 1. Criteria for metabolic phenotype classification. HDL high density lipoprotein cholesterol; HOMA-IR Homeostatic Model Assessment for Insulin Resistance ; hs-CRP high sensitive C-reactive protein
View article: Supplemental Table 7 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 7 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 7. Association between metabolic phenotypes defined by Wildman criteria with obesity-related cancer (ORC) risk after excluding participants diagnosed with ORC within the first three years of follow-up in the Women’s Heal…
View article: Supplemental Figure 7 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Figure 7 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Figure 7. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) with obesity-related cancer risk, stratified by cancer ty…
View article: Supplemental Figure 5 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Figure 5 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Figure 5. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by ATP III criteria with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s …
View article: Supplemental Figure 4 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Figure 4 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Figure 4. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by the Wildman criteria with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Wome…
View article: Supplemental Figure 6 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Figure 6 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Figure 6. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by C-Reactive Protein (hs-CRP) (A) ≥ 3 mg/L, (B) ≥ 10 mg/L with obesity-related cancer risk, stratified by cancer type amo…
View article: Supplemental Figure 1 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Figure 1 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Figure 1. Study Schematic of Women’s Health Initiative Participant Selection. Flowchart detailing the selection process of study participants, and the final cohort size for the study.
View article: Supplemental Table 5 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Supplemental Table 5 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Supplemental Table 5. Association between metabolic phenotypes defined by high sensitivity C-Reactive Protein (hs-CRP) ≥ 10 mg/L with obesity-related cancer risk in the Women’s Health Initiative cohort (N= 21,245).
View article: Reduced circulating sphingolipids and <i>CERS2</i> activity are linked to T2D risk and impaired insulin secretion
Reduced circulating sphingolipids and <i>CERS2</i> activity are linked to T2D risk and impaired insulin secretion Open
Gestational diabetes mellitus (GDM), a transient form of diabetes that resolves postpartum, is a major risk factor for type 2 diabetes (T2D) in women. While the progression from GDM to T2D is not fully understood, it involves both genetic …
View article: Targeting and reducing neuronal ceramide overaccumulation in 5xFAD mice improves AD pathologies and cognitive function
Targeting and reducing neuronal ceramide overaccumulation in 5xFAD mice improves AD pathologies and cognitive function Open
Background Neurodegenerative disorders such as Alzheimer’s Disease (AD) are increasingly associated with irregular lipid accumulation. Dysfunction in the catabolism of sphingolipids leads to many neurodegenerative disorders but has only re…
View article: Bwa, an ortholog of alkaline ceramidase-ACER2, promotes intestinal stem cell proliferation through pro-inflammatory cytokine signaling in<i>Drosophila melanogaster</i>
Bwa, an ortholog of alkaline ceramidase-ACER2, promotes intestinal stem cell proliferation through pro-inflammatory cytokine signaling in<i>Drosophila melanogaster</i> Open
Sphingolipids, including ceramides, are an important component of high-fat diets. These molecules can regulate fatty acid oxidation and intestinal stem cell proliferation, predisposing the gut to tumorigenesis. However, the molecular mecha…
View article: Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative Open
Body mass index (BMI) may misclassify obesity-related cancer (ORC) risk, as metabolic dysfunction can occur across BMI levels. We hypothesized that metabolic dysfunction at any BMI increases ORC risk compared with normal BMI without metabo…
View article: Cardiolipin deficiency disrupts electron transport chain to drive steatohepatitis
Cardiolipin deficiency disrupts electron transport chain to drive steatohepatitis Open
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive disorder marked by lipid accumulation, leading to metabolic dysfunction-associated steatohepatitis (MASH). A key feature of the transition to MASH involves o…
View article: Plasma ceramides as biomarkers for microvascular disease and clinical outcomes in diabetes and myocardial infarction
Plasma ceramides as biomarkers for microvascular disease and clinical outcomes in diabetes and myocardial infarction Open
Background Ceramides have recently been identified as novel biomarkers associated with diabetes mellitus (DM) and major adverse cardiac and cerebrovascular events (MACCE). This study aims to explore their utility in diagnosing microvascula…